CN Patent

CN107530337B — 治疗方法

Assigned to Baker IDI Heart and Diabetes Institute Holdings Ltd · Expires 2021-07-09 · 5y expired

What this patent protects

本发明涉及使用强心剂5‑(吡啶基)‑2(1H)‑吡啶酮化合物的缓释制剂治疗患有射血分数保留的心力衰竭(HFpEF)的个体的方法。

USPTO Abstract

本发明涉及使用强心剂5‑(吡啶基)‑2(1H)‑吡啶酮化合物的缓释制剂治疗患有射血分数保留的心力衰竭(HFpEF)的个体的方法。

Drugs covered by this patent

Dexilant (DEXLANSOPRAZOLE) · Takeda

Patent Metadata

Patent number: CN107530337B
Jurisdiction: CN
Classification: —
Expires: 2021-07-09
Drug substance claim: No
Drug product claim: No
Assignee: Baker IDI Heart and Diabetes Institute Holdings Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.